Medpace Holdings, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Medpace Holdings, Inc. (MEDP) reported Net Income (Loss) Available to Common Stockholders, Basic of $451.12 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-10.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-02-10
- Medpace Holdings, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was $135.13M, a 15.48% increase year-over-year.
- Medpace Holdings, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was $111.14M, a 15.25% increase year-over-year.
- Medpace Holdings, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-06-30 was $90.26M, a 2.16% increase year-over-year.
- Medpace Holdings, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-03-31 was $114.59M, a 11.75% increase year-over-year.
- Medpace Holdings, Inc. net income (loss) available to common stockholders, basic for fiscal 2025 was $451.12M, a 11.57% increase from fiscal 2024.
- Medpace Holdings, Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was $404.34M, a 43.07% increase from fiscal 2023.
- Medpace Holdings, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was $282.62M, a 15.26% increase from fiscal 2022.
- Medpace Holdings, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was $245.21M, a 35.18% increase from fiscal 2021.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2025-12-31 | $135.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $246.27M derived: sum of 2 quarters · filed 2026-02-10 | $336.53M derived: sum of 3 quarters · filed 2026-02-10 | $451.12M 10-K · filed 2026-02-10 |
| 2025-09-30 | $111.14M 10-Q · filed 2025-10-23 | $201.40M derived: sum of 2 quarters · filed 2025-10-23 | $315.99M 10-Q · filed 2025-10-23 | $433.00M derived: sum of 4 quarters · filed 2026-02-10 |
| 2025-06-30 | $90.26M 10-Q · filed 2025-07-22 | $204.85M 10-Q · filed 2025-07-22 | $321.87M derived: sum of 3 quarters · filed 2026-02-10 | $418.30M derived: sum of 4 quarters · filed 2026-02-10 |
| 2025-03-31 | $114.59M 10-Q · filed 2025-04-22 | $231.61M derived: sum of 2 quarters · filed 2026-02-10 | $328.04M derived: sum of 3 quarters · filed 2026-02-10 | $416.39M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-12-31 | $117.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $213.44M derived: sum of 2 quarters · filed 2026-02-10 | $301.79M derived: sum of 3 quarters · filed 2026-02-10 | $404.34M 10-K · filed 2026-02-10 |
| 2024-09-30 | $96.43M 10-Q · filed 2025-10-23 | $184.78M derived: sum of 2 quarters · filed 2025-10-23 | $287.33M 10-Q · filed 2025-10-23 | $365.57M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-30 | $88.35M 10-Q · filed 2025-07-22 | $190.90M 10-Q · filed 2025-07-22 | $269.14M derived: sum of 3 quarters · filed 2026-02-10 | $339.64M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-31 | $102.55M 10-Q · filed 2025-04-22 | $180.79M derived: sum of 2 quarters · filed 2026-02-10 | $251.29M derived: sum of 3 quarters · filed 2026-02-10 | $312.32M derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-31 | $78.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $148.75M derived: sum of 2 quarters · filed 2026-02-10 | $209.77M derived: sum of 3 quarters · filed 2026-02-10 | $282.62M 10-K · filed 2026-02-10 |
| 2023-09-30 | $70.50M 10-Q · filed 2024-10-22 | $131.53M derived: sum of 2 quarters · filed 2024-10-22 | $204.37M 10-Q · filed 2024-10-22 | $273.00M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | $61.03M 10-Q · filed 2024-07-23 | $133.87M 10-Q · filed 2024-07-23 | $202.50M derived: sum of 3 quarters · filed 2025-02-11 | $268.48M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $72.84M 10-Q · filed 2024-04-23 | $141.47M derived: sum of 2 quarters · filed 2025-02-11 | $207.45M derived: sum of 3 quarters · filed 2025-02-11 | $256.78M derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-31 | $68.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $134.61M derived: sum of 2 quarters · filed 2025-02-11 | $183.94M derived: sum of 3 quarters · filed 2025-02-11 | $245.21M 10-K · filed 2025-02-11 |
| 2022-09-30 | $65.98M 10-Q · filed 2023-10-24 | $115.31M derived: sum of 2 quarters · filed 2023-10-24 | $176.59M 10-Q · filed 2023-10-24 | $226.58M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | $49.33M 10-Q · filed 2023-07-25 | $110.60M 10-Q · filed 2023-07-25 | $160.60M derived: sum of 3 quarters · filed 2024-02-13 | $209.02M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | $61.27M 10-Q · filed 2023-04-25 | $111.27M derived: sum of 2 quarters · filed 2024-02-13 | $159.69M derived: sum of 3 quarters · filed 2024-02-13 | $199.50M derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | $49.99M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $98.42M derived: sum of 2 quarters · filed 2024-02-13 | $138.22M derived: sum of 3 quarters · filed 2024-02-13 | $181.39M 10-K · filed 2024-02-13 |
| 2021-09-30 | $48.42M 10-Q · filed 2022-10-25 | $88.23M derived: sum of 2 quarters · filed 2022-10-25 | $131.40M 10-Q · filed 2022-10-25 | $182.06M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | $39.81M 10-Q · filed 2022-07-26 | $82.97M 10-Q · filed 2022-07-26 | $133.63M derived: sum of 3 quarters · filed 2023-02-14 | $174.96M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | $43.17M 10-Q · filed 2022-04-26 | $93.83M derived: sum of 2 quarters · filed 2023-02-14 | $135.15M derived: sum of 3 quarters · filed 2023-02-14 | $159.19M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | $50.66M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $91.98M derived: sum of 2 quarters · filed 2023-02-14 | $116.02M derived: sum of 3 quarters · filed 2023-02-14 | $144.93M 10-K · filed 2023-02-14 |
| 2020-09-30 | $41.33M 10-Q · filed 2021-10-26 | $65.36M derived: sum of 2 quarters · filed 2021-10-26 | $94.27M 10-Q · filed 2021-10-26 | $123.97M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $24.04M 10-Q · filed 2021-07-27 | $52.92M 10-Q · filed 2021-07-27 | $82.65M derived: sum of 3 quarters · filed 2022-02-15 | $106.56M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $28.88M 10-Q · filed 2021-04-27 | $58.61M derived: sum of 2 quarters · filed 2022-02-15 | $82.52M derived: sum of 3 quarters · filed 2022-02-15 | $109.90M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $29.73M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $53.65M derived: sum of 2 quarters · filed 2022-02-15 | $81.02M derived: sum of 3 quarters · filed 2022-02-15 | $100.16M 10-K · filed 2022-02-15 |
| 2019-09-30 | $23.91M 10-Q · filed 2020-10-27 | $51.29M derived: sum of 2 quarters · filed 2020-10-27 | $70.43M 10-Q · filed 2020-10-27 | $93.11M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-06-30 | $27.38M 10-Q · filed 2020-07-28 | $46.52M 10-Q · filed 2020-07-28 | $69.19M derived: sum of 3 quarters · filed 2021-02-16 | $88.42M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-03-31 | $19.14M 10-Q · filed 2020-04-29 | $41.82M derived: sum of 2 quarters · filed 2021-02-16 | $61.05M derived: sum of 3 quarters · filed 2021-02-16 | $77.55M derived: sum of 4 quarters · filed 2021-02-16 |
| 2018-12-31 | $22.67M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | $41.90M derived: sum of 2 quarters · filed 2021-02-16 | $58.40M derived: sum of 3 quarters · filed 2021-02-16 | $72.89M 10-K · filed 2021-02-16 |
| 2018-09-30 | $19.23M 10-Q · filed 2019-10-29 | $35.73M derived: sum of 2 quarters · filed 2019-10-29 | $50.22M 10-Q · filed 2019-10-29 | $61.46M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | $16.50M 10-Q · filed 2019-07-30 | $30.99M 10-Q · filed 2019-07-30 | $42.23M derived: sum of 3 quarters · filed 2020-02-25 | $52.05M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | $14.49M 10-Q · filed 2019-04-30 | $25.73M derived: sum of 2 quarters · filed 2020-02-25 | $35.55M derived: sum of 3 quarters · filed 2020-02-25 | $45.09M derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | $11.24M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $21.06M derived: sum of 2 quarters · filed 2020-02-25 | $30.60M derived: sum of 3 quarters · filed 2020-02-25 | $39.03M 10-K · filed 2020-02-25 |
| 2017-09-30 | $9.81M 10-Q · filed 2018-10-30 | $19.35M derived: sum of 2 quarters · filed 2018-10-30 | $27.79M 10-Q · filed 2018-10-30 | $27.73M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-06-30 | $9.54M 10-Q · filed 2018-07-31 | $17.97M 10-Q · filed 2018-07-31 | $17.92M derived: sum of 3 quarters · filed 2019-02-26 | $22.96M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-03-31 | $8.44M 10-Q · filed 2018-05-01 | $8.38M derived: sum of 2 quarters · filed 2019-02-26 | $13.42M derived: sum of 3 quarters · filed 2019-02-26 | $18.38M derived: sum of 4 quarters · filed 2019-02-26 |
| 2016-12-31 | -$54.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $4.98M derived: sum of 2 quarters · filed 2019-02-26 | $9.94M derived: sum of 3 quarters · filed 2019-02-26 | $13.39M 10-K · filed 2019-02-26 |
| 2016-09-30 | $5.04M 10-Q · filed 2017-10-31 | $10.00M derived: sum of 2 quarters · filed 2017-10-31 | $13.45M 10-Q · filed 2017-10-31 | |
| 2016-06-30 | $4.96M 10-Q · filed 2017-08-01 | $8.41M 10-Q · filed 2017-08-01 | ||
| 2016-03-31 | $3.45M 10-Q · filed 2017-05-02 | |||
| 2015-12-31 | -$8.67M 10-K · filed 2018-02-27 | |||
| 2014-12-31 | -$14.34M 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |